Literature DB >> 12878482

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.

Hiroshi Hasegawa1, Rie Yamamoto, Hiroyuki Takano, Miho Mizukami, Masayuki Asakawa, Toshio Nagai, Issei Komuro.   

Abstract

OBJECTIVES: The aim of the present study was to determine whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have preventive effects on the development of cardiac hypertrophy and heart failure.
BACKGROUND: Statins have been reported to have various pleiotropic effects, such as inhibition of inflammation and cell proliferation.
METHODS: Dahl rats were divided into three groups: LS, the rats fed the low-salt diet (0.3% NaCl); HS, the rats fed the high-salt diet (8% NaCl) from the age of 6 weeks; and CERI, the rats fed the high-salt diet with cerivastatin 1 mg/kg/d by gavage from the age of 6 weeks.
RESULTS: In HS rats, cardiac function was markedly impaired and all rats showed the signs of heart failure within 17 weeks of age. In CERI rats, cardiac function was better than that of HS and no rats were dead up to 17 weeks of age. The development of cardiac hypertrophy and fibrosis was attenuated, and the number of apoptotic cells and expression of proinflammatory cytokine interleukin (IL)-1beta gene were less as compared with HS rats. Pretreatment of cerivastatin suppressed the adriamycin-induced apoptosis of cultured cardiomyocytes of neonatal rats.
CONCLUSIONS: These results suggest that statins have a protective effect on cardiac myocytes and may be useful to prevent the development of hypertensive heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878482     DOI: 10.1016/s0022-2828(03)00180-9

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

Review 1.  Statin therapy in heart failure: for good, for bad, or indifferent?

Authors:  Luisa De Gennaro; Natale Daniele Brunetti; Michele Correale; Francesco Buquicchio; Pasquale Caldarola; Matteo Di Biase
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

Review 2.  Spectrum of pleiotropic effects of statins in heart failure.

Authors:  Nitin Mathur; Kumudha Ramasubbu; Douglas L Mann
Journal:  Heart Fail Clin       Date:  2008-04       Impact factor: 3.179

Review 3.  Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue?

Authors:  Emily L Ongstad; Robert G Gourdie
Journal:  Semin Cell Dev Biol       Date:  2016-05-24       Impact factor: 7.727

4.  Transient receptor potential (TRP) protein 7 acts as a G protein-activated Ca2+ channel mediating angiotensin II-induced myocardial apoptosis.

Authors:  Shinji Satoh; Haruki Tanaka; Yasuko Ueda; Jun-Ichi Oyama; Masahiro Sugano; Hideki Sumimoto; Yasuo Mori; Naoki Makino
Journal:  Mol Cell Biochem       Date:  2006-07-13       Impact factor: 3.396

Review 5.  Statins and the myocardium.

Authors:  Seema Mital; James K Liao
Journal:  Semin Vasc Med       Date:  2004-11

6.  Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin.

Authors:  Hiroyuki Ihori; Takashi Nozawa; Mitsuo Sobajima; Takuya Shida; Yasutaka Fukui; Nozomu Fujii; Hiroshi Inoue
Journal:  Heart Vessels       Date:  2015-12-19       Impact factor: 2.037

Review 7.  Statin therapy for cardiac hypertrophy and heart failure.

Authors:  James K Liao
Journal:  J Investig Med       Date:  2004-05       Impact factor: 2.895

Review 8.  Combined antihypertensive and lipid-lowering treatment.

Authors:  Maurizio Cesari; Achille C Pessina
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

Review 9.  Statins and congestive heart failure.

Authors:  Jennifer Martin
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

Review 10.  Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.

Authors:  Alexios S Antonopoulos; Marios Margaritis; Regent Lee; Keith Channon; Charalambos Antoniades
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.